SCHEMBL10067291

SCHEMBL10067291

Clc1ccc(-c2[nH]c3ccccc3c2-c2nc3c4cccnc4c4ncccc4c3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.44
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
PTGES O14684 7/20 0.43
JAK2 O60674 2/20 0.43
TBXAS1 P24557 1/20 0.42
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
PARP1 P09874 1/20 0.41
MAPK14 Q16539 2/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
MET P08581 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067268 0.90 ESR1 (0.50) PTGS2TDO2PTGESJAK2CDK4
SCHEMBL17368965 0.89 PARP1 (0.42) IDO1TDO2PTGESJAK2CDK4
SCHEMBL10067258 0.88 MAPK14 (0.54) PTGS2PTGESJAK2CDK4CCND1
SCHEMBL10067270 0.88 MAPK14 (0.50) PTGESJAK2CDK4CCND1PARP1
SCHEMBL30338162 0.85 TNKS (0.48) IDO1TDO2PTGESJAK2TBXAS1
SCHEMBL10067259 0.84 PTGES (0.44) PTGESJAK2TBXAS1CDK4CCND1
SCHEMBL10067256 0.79 MEN1 (0.56) CDK4CCND1PARP1
SCHEMBL14023501 0.78 ESR1 (0.57) PTGS2IDO1TDO2PTGESJAK2
SCHEMBL10067282 0.78 MAP3K14 (0.50) PTGESJAK2TBXAS1
SCHEMBL14579767 0.77 MAP4K4 (0.47) IDO1TDO2PTGESPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
WO-2010102393-A1 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS LORUS THERAPEUTICS INC. (CA) 2010-09-16 WO disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 PTGS2 895/4885IDO1 46/4885TDO2 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.